Navigation Links
Par Pharmaceutical Begins Shipment of Generic Zyprexa® Zydis®
Date:10/24/2011

WOODCLIFF LAKE, N.J., Oct. 24, 2011 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it began shipping the 5mg, 10mg, 15mg, and 20mg strengths of olanzapine orally disintegrating tablets, the generic version of Lilly's Zyprexa® Zydis®. According to IMS Health data, annual sales in the U.S. of Zyprexa® Zydis® are approximately $360 million.

Important information about olanzapine ODT

Olanzapine is an atypical antipsychotic indicated as oral formulation for the:

  • Treatment of schizophrenia.
  • Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder.
  • Medication therapy for pediatric patients with schizophrenia or bipolar I disorder should be undertaken only after a thorough diagnostic evaluation and with careful consideration of the potential risks
  • Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar I disorder.

There are no labeled contraindications for olanzapine monotherapy. However, when using in combination with lithium or valproate, refer to the Contraindications section of the package inserts for those products.

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Olanzapine orally disintegrating tablets are not approved for the treatment of patients with dementia-related psychosis. Refer to full prescribing information for complete boxed WARNING.

About Par Pharmaceutical Companies, Inc.

Par Pharmaceutical Companies, Inc. is a U.S.-based specialty pharmaceutical company. Through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures and markets higher-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals. For press releases and other company information, visit www.parpharm.com.

Safe Harbor Statement

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's most recent Annual Report on Form 10-K, in other of the Company's filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 22, 2017  CVS Pharmacy is the first national ... hydrogenated oils (PHO), the primary source of artificial trans ... brands food products. The retailer now offers over 600 ... artificial trans fats. This comes a year and a half ... June 2018 for processed foods to be reformulated without ...
(Date:2/22/2017)... HAMBURG, Germany , February 22, 2017 ... Hamburg, Germany and The Indian Institute of ... a collaboration to support the first Indian national cancer data base ... ... with an initial three-year term. The collaboration will include collection of ...
(Date:2/21/2017)... 21, 2017 Micro Guide Catheters Market: ... http://www.reportlinker.com/p04711314-summary/view-report.html Micro Guide Catheters are ... specialty clinics and ambulatory surgery centers etc. Micro ... The selection of micro guide catheter depends on ... human body. Micro guide catheters are available in ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... ANGLESTRONG , the new recovery ... available on the App Store and Google Play . Florida-based Sober ... addiction and recovery industry, partnered with Angle to build ANGLESTRONG. The new recovery management ...
(Date:2/22/2017)... ... February 22, 2017 , ... Michael ... new media platform connecting healthcare technology professionals and other key stakeholders with an ... quarterly publication starting on March 1, announced Michael J. Hennessy, Jr., president of ...
(Date:2/22/2017)... ... February 22, 2017 , ... Social media marketing is transitioning from a singular ... Smith & Jones’ delves into this insight and more in its latest episode of ... David Vener meets up with social media strategist and partner of the digital firm ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... - the Vector™ Series Multi-Cook Oven offers up to four ovens in one. ... Structured Air Technology™ for unmatched evenness in cooking. Alto-Shaam has partnered with Appliance ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... five new hospital-grade power extension cords that meet the most current standards. , ... 2012 edition of the National Fire Protection Association (NFPA) 101 – Life Safety ...
Breaking Medicine News(10 mins):